Drugs that contain Brimonidine Tartrate

1. List of Alphagan P drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6562873

(Pediatric)

ALLERGAN Compositions containing therapeutically active components having enhanced solubility
Jan, 2022

(1 year, 30 days ago)

US9295641

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(1 year, 30 days ago)

US9687443

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(1 year, 30 days ago)

US6627210

(Pediatric)

ALLERGAN Compositions containing α-2-adrenergic agonist components
Jan, 2022

(1 year, 22 days ago)

US6673337

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(1 year, 14 days ago)

US6641834

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(1 year, 12 days ago)

US8858961 ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Sep, 2023

(6 months from now)

US8858961

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Mar, 2024

(1 year, 21 days from now)

Market Authorisation Date: 16 March, 2001

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ALPHAGAN P before it's patent expiration?
More Information on Dosage

ALPHAGAN P family patents

15

United States

5

Australia

5

Japan

3

Canada

2

Brazil

2

Mexico

2

China

2

New Zealand

1

Hong Kong

1

Korea, Republic of

1

Poland

1

Israel

1

Hungary

1

Argentina

1

South Africa

1

Russia

1

Norway

1

Taiwan, Province of China

1

European Union

2. List of Lumify drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259425 BAUSCH AND LOMB INC Compositions and methods for eye whitening
Jul, 2030

(7 years from now)

US8293742 BAUSCH AND LOMB INC Preferential vasoconstriction compositions and methods of use
Jul, 2030

(7 years from now)

Market Authorisation Date: 22 December, 2017

Treatment: Relieves redness of the eye due to minor eye irritations

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LUMIFY before it's patent expiration?
More Information on Dosage

LUMIFY family patents

42

United States

4

Canada

4

Japan

4

European Union

2

Spain

1

Slovenia

1

Denmark

1

Korea, Republic of

1

Brazil

1

San Marino

1

Poland

1

Portugal

1

Cyprus

1

Russia

1

Croatia

1

Mexico

3. List of Mirvaso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859551 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
May, 2024

(1 year, 3 months from now)

US8231885 GALDERMA LABS LP Compounds, formulations, and methods for ameliorating telangiectasis
May, 2025

(2 years from now)

US8410102 GALDERMA LABS LP Methods and compositions for treating or preventing erythema
May, 2025

(2 years from now)

US8426410 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
May, 2025

(2 years from now)

US7439241 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing rosacea
Aug, 2025

(2 years from now)

US8513247 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(8 years from now)

US9861632 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(8 years from now)

US9861631 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(8 years from now)

US8513249 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(8 years from now)

US8053427 GALDERMA LABS LP Brimonidine gel composition
Jun, 2031

(8 years from now)

US8163725 GALDERMA LABS LP Gel compositions and methods of use
Jun, 2031

(8 years from now)

US10201517 GALDERMA LABS LP Brimonidine gel compositions and methods of use
Jun, 2031

(8 years from now)

Market Authorisation Date: 23 August, 2013

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

How can I launch a generic of MIRVASO before it's patent expiration?
More Information on Dosage

MIRVASO family patents

40

United States

10

European Union

9

China

7

Spain

6

Poland

6

Portugal

6

Denmark

5

Korea, Republic of

5

Japan

5

Slovenia

5

Canada

4

Australia

4

Cyprus

4

Mexico

4

Hungary

3

Hong Kong

3

Brazil

3

Israel

3

New Zealand

2

South Africa

2

Russia

2

Croatia

2

Norway

1

Austria

1

RS

1

Lithuania

1

Luxembourg

1

Argentina

1

Singapore

1

San Marino

1

France

4. List of Qoliana drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7265117 SANDOZ INC Topical brimonidine tartrate formulations that lack chlorine dioxide
Aug, 2025

(2 years from now)

Market Authorisation Date: 22 May, 2006

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic